A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

January 14, 2025

Study Completion Date

January 14, 2025

Conditions
Alopecia Areata (AA)
Interventions
DRUG

IMG-007

Intravenous Infusion

Trial Locations (17)

14623

Skin Search of Rochester, Inc., Rochester

33615

Alliance Clinical Research of Tampa, Tampa

47906

Dawes Fretzin Clinical Resarch Group, LLC, Indianapolis

Options Research Group, West Lafayette

48706

Great Lakes Research Group Inc., Bay City

72758

Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A., Rogers

77479

Stride Clinical Research LLC, Sugar Land

89509

Skin Cancer and Dermatology Institute, Reno

90717

Torrance Clinical Research Institute Inc., Lomita

99202

Dermatology Specialists of Spokane, Spokane

01803

Lahey Hospital & Medical Center, Burlington

L4M7G1

SimcoMed Health Ltd., Barrie

K9A0Z4

Skin Health, Cobourg

N1L0B7

Guelph Dermatology Research, Guelph

M2W2N4

Research Toronto, Toronto

G1W4R4

Centre de Recherche Saint-Louis, Québec

Unknown

Innovaderm Research Inc., Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Inmagene LLC

INDUSTRY

NCT06060977 - A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants | Biotech Hunter | Biotech Hunter